BMIQ1
MCID: BDY007
MIFTS: 42

Body Mass Index Quantitative Trait Locus 1 (BMIQ1)

Categories: Bone diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 56 13
Body Mass Index 56 17
Bmi 56 47
Body Mass Index; Bmi 56
Bmiq1 56

Classifications:



External Ids:

OMIM 56 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM : 56 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). For discussion of genetic heterogeneity of BMI quantitative trait loci and their known or possible associations with variation in specific genes, see MAPPING and MOLECULAR GENETICS sections. (606641)

MalaCards based summary : Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 3 and body mass index quantitative trait locus 2. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Mecasermin and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and liver.

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1091)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 3 12.7
2 body mass index quantitative trait locus 2 12.7
3 body mass index quantitative trait locus 5 12.7
4 body mass index quantitative trait locus 6 12.7
5 body mass index quantitative trait locus 13 12.7
6 body mass index quantitative trait locus 15 12.7
7 esophageal cancer 11.8
8 chromosome 16p11.2 deletion syndrome, 220-kb 11.5
9 siddiqi syndrome 11.5
10 hypercholesterolemia, familial, 3 11.3
11 mental retardation, x-linked 12 11.2
12 morbid obesity and spermatogenic failure 11.2
13 chronic kidney disease 10.7
14 arteries, anomalies of 10.7
15 hyperlipoproteinemia, type iii 10.7
16 coronary artery anomaly 10.7
17 kidney disease 10.7
18 hypercholesterolemia, familial, 1 10.6
19 pulmonary disease, chronic obstructive 10.6
20 end stage renal failure 10.6
21 eclampsia 10.6
22 rectum cancer 10.6
23 congestive heart failure 10.6
24 renal cell carcinoma, nonpapillary 10.6
25 pancreatic cancer 10.6
26 pustulosis of palm and sole 10.6
27 psoriasis 10.6
28 diabetes mellitus 10.6
29 ovarian cancer 10.5
30 atrial fibrillation 10.5
31 back pain 10.5
32 acute myocardial infarction 10.5
33 lung cancer 10.5
34 asthma 10.5
35 cerebrovascular disease 10.5
36 ige responsiveness, atopic 10.5
37 ischemia 10.5
38 adenocarcinoma 10.5
39 hyperandrogenism 10.5
40 hypothyroidism 10.5
41 precocious puberty 10.5
42 myocardial infarction 10.5
43 central precocious puberty 10.5
44 prostate cancer 10.4
45 rheumatoid arthritis 10.4
46 fatty liver disease, nonalcoholic 1 10.4
47 peripheral vascular disease 10.4
48 hyperuricemia 10.4
49 spinal cord injury 10.4
50 thyroid carcinoma 10.4

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM:

606641

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1069)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecasermin Approved, Investigational Phase 4 68562-41-4
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
5
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
6
Linagliptin Approved Phase 4 668270-12-0 10096344
7
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
8
Succinylcholine Approved Phase 4 306-40-1 5314
9
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
10
Nifedipine Approved Phase 4 21829-25-4 4485
11
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
12
Atenolol Approved Phase 4 29122-68-7 2249
13
Nebivolol Approved, Investigational Phase 4 99200-09-6, 152520-56-4, 118457-14-0 71301
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
17
Sertraline Approved Phase 4 79617-96-2 68617
18
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
19
Ethambutol Approved Phase 4 74-55-5 3279 14052
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
22
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
23
Lorazepam Approved Phase 4 846-49-1 3958
24
Ziprasidone Approved Phase 4 146939-27-7 60854
25
Desflurane Approved Phase 4 57041-67-5 42113
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
27
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
28
Memantine Approved, Investigational Phase 4 19982-08-2 4054
29
Vancomycin Approved Phase 4 1404-90-6 441141 14969
30
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
31
Racepinephrine Approved Phase 4 329-65-7 838
32
Sultamicillin Approved, Investigational Phase 4 76497-13-7
33
Sulbactam Approved Phase 4 68373-14-8
34
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
35
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
36
Voriconazole Approved Phase 4 137234-62-9 71616
37
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
38
Drospirenone Approved Phase 4 67392-87-4 68873
39
Fenofibrate Approved Phase 4 49562-28-9 3339
40
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
41
Potassium citrate Approved, Investigational, Vet_approved Phase 4
42
Nadroparin Approved, Investigational Phase 4
43
Carbetocin Approved, Investigational Phase 4 37025-55-1 71715 16681432
44
Histamine Approved, Investigational Phase 4 51-45-6 774
45
Amlodipine Approved Phase 4 88150-42-9 2162
46
Glyburide Approved Phase 4 10238-21-8 3488
47
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
48
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
49
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
50
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829

Interventional clinical trials:

(show top 50) (show all 3785)
# Name Status NCT ID Phase Drugs
1 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
2 A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules
3 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
4 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
5 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
6 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
7 Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol Unknown status NCT00611780 Phase 4
8 The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
9 Effect of Enteral Nutrition in the Outcome of Patients With Cardiovascular Surgery Unknown status NCT01432769 Phase 4
10 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
11 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
12 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
13 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
14 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
15 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
16 Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension Unknown status NCT02894723 Phase 4
17 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
18 A Double-blind, Randomized, Controlled, Equivalence Study Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections Unknown status NCT02612272 Phase 4 Ketorolac;Betamethasone
19 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
20 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
21 Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery Unknown status NCT02521402 Phase 4
22 Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting Unknown status NCT02568020 Phase 4 keto-amino acids
23 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
24 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
25 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
26 Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
27 Study on the Effect of Combined Oral Contraceptive Therapy on Female Sexuality, Body Image and Mental Health Unknown status NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
28 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
29 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
30 Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
31 Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience Unknown status NCT02504749 Phase 4
32 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
33 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
34 Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial Unknown status NCT02967029 Phase 4 Esmolol Hydrochloride;Remifentanil Hydrochloride
35 Efficacy of Vitamin D Supplementation in Obese Children Unknown status NCT02956408 Phase 4
36 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
37 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
38 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
39 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
40 Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial Unknown status NCT02930057 Phase 4 Celestone;Control
41 Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
42 The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes Completed NCT00778622 Phase 4 Metformin XR
43 Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease Completed NCT00934570 Phase 4 Metformin and standard exercise;Metformin Intensive exercise
44 Improving Contraceptive Effectiveness in Obese Women Completed NCT01170390 Phase 4 All participants (Aviane);Portia;Aviane
45 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
46 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
47 Bioavailability Study of Omeprazole (20 mg) at Steady State (Multiple Dose) in Patients Who Have Undergone Bariatric Surgery Completed NCT03378960 Phase 4 Omeprazole 20mg
48 A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET) Completed NCT01232491 Phase 4 Insulin detemir
49 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
50 Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

40
Breast, Heart, Liver, Bone, Kidney, Ovary, Testes

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 30006)
# Title Authors PMID Year
1
New genetic loci link adipose and insulin biology to body fat distribution. 61 56
25673412 2015
2
Genetic studies of body mass index yield new insights for obesity biology. 56 61
25673413 2015
3
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. 56 61
21706003 2011
4
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. 61 56
20935630 2010
5
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. 56 61
14569127 2003
6
A study of linkage and association of body mass index in the Old Order Amish. 56 61
12888987 2003
7
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. 61 56
12355400 2002
8
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. 61 56
11713718 2002
9
Familial aggregation of body mass index and subcutaneous fat measures in the longitudinal Québec family study. 56 61
10096693 1999
10
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. 56 61
9806549 1998
11
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. 61 56
9758619 1998
12
The genetic contribution to non-syndromic human obesity. 56
19506576 2009
13
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 56
19151714 2009
14
Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. 56
17855449 2007
15
Genetic pleiotropy between asthma and obesity in a community-based sample of twins. 56
16337451 2005
16
Genome-wide scan of obesity in the Old Order Amish. 56
11238509 2001
17
Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. 56
10523018 1999
18
The association of body mass index with same-day hospital admission, postoperative complications, and 30-day readmission following day-case eligible joint arthroscopy: A national registry analysis. 61
31200188 2020
19
Risk factors for periprosthetic joint infection of the hip and knee. 61
31432657 2020
20
Prepregnancy Body Mass Index shift across gestation: primary evidence of an association with eating disorders. 61
29950130 2020
21
Plasma Leptin Does Not Reflect the Effect of High Body Mass Index on Disease Activity in Rheumatoid Arthritis. 61
31223038 2020
22
The development of executive function in early childhood is inversely related to change in body mass index: Evidence for an energetic tradeoff? 61
31102547 2020
23
Secular trends in the grip strength and body mass index of sport university students between 1973 and 2016: J-Fit+study. 61
31641364 2020
24
Pregestational body mass index, weight gain during pregnancy and perinatal outcome: a retrospective descriptive study. 61
31721895 2020
25
Correlation between nutritional assessment and oxidative stress in candidates for liver transplant. 61
31851223 2020
26
The effects of curcumin supplementation on body weight, body mass index and waist circumference: a systematic review and dose-response meta-analysis of randomized controlled trials. 61
30373373 2020
27
Relationship between weight status and cognition in children: A mediation analysis of physical fitness components. 61
31597515 2020
28
Impact of Nutrition on Cardiovascular Function. 61
30318107 2020
29
Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia. 61
31688623 2020
30
The Impact of Body Mass Index on Perioperative and Postoperative Outcomes for Endovascular Abdominal Aneurysm Repair. 61
30710629 2020
31
Association between Body Mass Index and Stroke Risk Among Patients with Type 2 Diabetes. 61
31529060 2020
32
Body mass index and the risk of disability retirement: a systematic review and meta-analysis. 61
31467042 2020
33
Body Mass Index Change Between Referral to and Enrollment in Pediatric Weight Management. 61
31658819 2020
34
Challenges in obesity and primary aldosteronism: Diagnosis and treatment. 61
31542169 2020
35
Relationship Between Obesity and Balance in the Community-Dwelling Elderly Population: A Cross-Sectional Analysis. 61
31464747 2020
36
Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals. 61
30815851 2020
37
Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis. 61
31400455 2020
38
The temporal and long-term impact of donor body mass index on recipient outcomes after kidney transplantation - a retrospective study. 61
31478267 2020
39
Total Joint Arthroplasty in the Morbidly Obese: How Body Mass Index ≥40 Influences Patient Retention, Treatment Decisions, and Treatment Outcomes. 61
31530460 2020
40
Patient Characteristics Influence Revision Rate of Total Hip Arthroplasty: American Society of Anesthesiologists Score and Body Mass Index Were the Strongest Predictors for Short-Term Revision After Primary Total Hip Arthroplasty. 61
31506185 2020
41
Association between birth weight and diabetes: Role of body mass index and lifestyle in later life. 61
31170331 2020
42
Understanding the impact of age, gender, height and body mass index on children's balance. 61
31301080 2020
43
Relation of Change of Body Mass Index to Long-Term Mortality After Cardiac Catheterization. 61
31740019 2020
44
Should donor body mass index influence kidney utilization by transplant centers? 61
31554013 2020
45
The Role of Body Mass Index on Hearing Outcomes After Stapes Surgery. 61
31644475 2020
46
Synergic Impact of Body Mass Index, Diabetes, and Age on Long-Term Mortality in Japanese Incident Hemodialysis Patients: A Cohort Study on a Large National Dialysis Registry. 61
31812321 2019
47
Time spent watching television impacts on body mass index in youth with obesity, but only in those with shortest sleep duration. 61
31821651 2019
48
The Effect of Body Mass Index on Outcome after Endovascular Treatment in Acute Ischemic Stroke Patients: A Post Hoc Analysis of the MR CLEAN Trial. 61
31825939 2019
49
Contrasting Associations of Body Mass Index and Hemoglobin A1c on the Excess Risk of Acute Myocardial Infarction and Heart Failure in Type 2 Diabetes Mellitus. 61
31818213 2019
50
A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. 61
31818851 2019

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....